High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.

Hsieh, Yu-Ting; Chiang, Bing-Juin; Wu, Chia-Chang; Liao, Chun-Hou; Lin, Chia-Da; Chen, Chung-Hsin

Hsieh, Yu-Ting; Chiang, Bing-Juin; Wu, Chia-Chang; Liao, Chun-Hou; Lin, Chia-Da; Chen, Chung-Hsin.

Afiliação

Hsieh YT; Department of Urology, National Taiwan University Hospital, Taipei 10002, Taiwan.
Chiang BJ; Division of Urology, Department of Surgery, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City 23148, Taiwan.
Wu CC; Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.
Liao CH; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Lin CD; TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei 11031, Taiwan.
Chen CH; Division of Urology, Department of Surgery, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City 23148, Taiwan.

Cancers (Basel) ; 13(16)2021 Aug 05.

Article em En | MEDLINE | ID: mdl-34439119

Palavras-chave

enzalutamide; prognosis; prostate-specific antigen; prostatic neoplasms; tumor burden

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Taiwan País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google